The Difference Between Compounded and Generic Medications: A Layperson's Guide

why this distinction confuses everyone

If you take a prescription medication in the United States, there's a reasonable chance you've encountered one of the following three categories: a brand-name drug (Lipitor, Wegovy, Ozempic, Prozac), a generic drug (atorvastatin, sertraline, metformin), or a compounded medication (custom-formulated estrogen cream, peptide preparations, specific pediatric liquid formulations). These are three structurally different things, regulated through three different FDA pathways, produced under three different sets of standards.

Consumer understanding of the differences between them is, to put it gently, inconsistent. Many patients think 'generic' and 'compounded' are interchangeable terms. Many others think compounded medications are 'fake' or 'not real medicine.' Neither is accurate. The distinctions matter — for understanding what you're taking, for evaluating the claims that different pharmaceutical businesses make about their products, and for navigating the regulatory landscape as a consumer.

This guide is designed as layperson orientation. It doesn't require pharmaceutical training to understand. By the end, readers should be able to explain the three categories to another intelligent non-specialist and should be able to read pharmaceutical industry news with a clearer sense of what's actually happening under the regulatory hood.

brand-name drugs: the NDA pathway

Brand-name drugs — Lipitor, Wegovy, Ozempic, Humira, every FDA-approved product you've heard of — are approved through the New Drug Application (NDA) pathway. The NDA is the regulatory process that originally brings a new molecule to market.

What an NDA requires. The sponsor of an NDA (typically a pharmaceutical company) submits extensive evidence to the FDA demonstrating: - Safety across multiple clinical trial phases - Efficacy for specific indications (a drug is approved 'for the treatment of X condition in Y population') - Pharmaceutical manufacturing quality meeting current Good Manufacturing Practice (cGMP) standards - Labeling, packaging, and post-market surveillance commitments

An NDA typically takes 10-15 years from molecule identification to approval and costs hundreds of millions to billions of dollars depending on the drug's complexity. Once approved, the drug is protected by patents (typically 20 years from molecule filing, often less by the time the drug reaches market) and by data exclusivity provisions that prevent generic competition for a set period.

What brand approval guarantees. When you take a brand-name FDA-approved drug, you're taking a specific molecule, produced under audited cGMP manufacturing, with extensive clinical trial evidence supporting its efficacy for the specific approved indication. The label on the bottle tells you what's in it, how much, how it was made, and what the trial evidence supports.

What brand approval doesn't guarantee. FDA approval is for specific indications. A brand drug approved for condition X and prescribed off-label for condition Y is still being used outside the FDA-approved evidence base. Off-label use is legal and often appropriate — it's just not covered by the FDA approval itself.

generic drugs: the ANDA pathway

When the patent and data exclusivity on a brand-name drug expire, competitors can seek approval to market the same molecule as a generic under the Abbreviated New Drug Application (ANDA) pathway.

What an ANDA requires. An ANDA applicant does not need to repeat the safety and efficacy trials the original NDA required. Instead, they must demonstrate: - The generic product contains the same active ingredient as the brand, at the same strength, in the same dosage form - The product meets the same pharmaceutical manufacturing quality standards (cGMP) - The product is bioequivalent to the brand — typically demonstrated through pharmacokinetic studies showing that blood levels of the active ingredient over time track within a specified range of the brand product - The labeling and other regulatory requirements are met

The logic of the ANDA pathway is that the safety and efficacy of the molecule have already been established by the brand's NDA — the generic only needs to show that it delivers the same molecule to the bloodstream in the same way. This is why generic drugs are dramatically cheaper than brand: the ANDA pathway doesn't require replicating the clinical trials that the NDA required.

What generic approval guarantees. A generic drug is the same active ingredient as the brand, produced under cGMP standards, demonstrated to be bioequivalent to the brand within the FDA's accepted tolerances. It's the same medicine — not a different, weaker, or inferior version. This is a frequent consumer misconception.

What generic approval doesn't guarantee. Bioequivalence is defined within an accepted range (typically 80-125% of the brand's AUC — area under the pharmacokinetic curve). For most drugs, this range is clinically irrelevant. For drugs where the dose has to be very precise — lithium, warfarin (a blood thinner), some seizure medications — the small allowed variation between brand and generic can occasionally make a real difference for patients. The inactive ingredients — fillers, dyes, the stuff that holds the pill together — may differ between brand and generic, which can matter for patients with specific allergies or sensitivities.

compounded medications: the 503A and 503B pathways

Compounded medications are the third category — and the one that generates the most consumer confusion. Compounded medications are prepared by licensed pharmacies (not pharmaceutical manufacturers) under regulatory frameworks governed by Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act.

503A traditional compounding pharmacies. These are patient-specific compounding pharmacies licensed by state boards of pharmacy. They prepare medications in response to individual prescriptions, for specific patients, typically in small batches. They operate under the USP 795 (nonsterile) and USP 797 (sterile) compounding standards — these are real, legitimate pharmacy quality standards — but they're not as strict as cGMP, the standard that big drug factories have to meet.

503B outsourcing facilities. These are federal-registered facilities that can produce compounded medications in batches without patient-specific prescriptions, but under standards close to — though not quite — full pharmaceutical manufacturing rules. They are inspected by the FDA and subject to more rigorous quality oversight than 503A facilities. There are approximately 80 of them in the US.

What compounding does. Compounding pharmacies prepare medications customized for individual patients — different strengths than commercially available, different formulations (liquid versions of tablet-only drugs, combinations of multiple active ingredients, alternative delivery methods), different excipients for patients with specific allergies, or specific molecules that are not available as FDA-approved products.

What compounding doesn't do. Compounded medications are not FDA-approved. They have not gone through the NDA process, and they have not been demonstrated to be safe, effective, or bioequivalent to any FDA-approved product. The regulatory framework is different: the FDA regulates the pharmacy's compounding activities and the sourcing of active pharmaceutical ingredients, but individual compounded products are not themselves FDA-approved.

This is the most important point for consumers: 'compounded' and 'FDA-approved' are different categories. A compounded medication is a legitimate prescription medication prepared by a licensed pharmacy, but it is not FDA-approved in the way that brand and generic drugs are.

the three categories side by side

The table makes the structural difference clear. Brand and generic drugs are the 'FDA-approved pharmaceutical' category — different pricing, same regulatory pathway and standards. Compounded medications are structurally different — not FDA-approved, but legally produced under a separate regulatory framework designed for patient-specific customization.

what compounded medications are appropriately used for

Compounded medications serve legitimate clinical needs that FDA-approved pharmaceuticals don't cover. The main use cases:

Patient-specific customization. A patient who needs a specific dose that isn't commercially available (a child who needs a liquid version of an adult tablet, a patient who needs a specific strength between two commercial strengths). A patient who needs a combination of two active ingredients that isn't commercially available as a combination product.

Allergies to inactive ingredients. A patient who is allergic to a specific dye, binder, or excipient in an FDA-approved product can have a compounded version prepared without the allergen.

Alternative delivery methods. A compounded cream or suppository version of a medication that's only commercially available as an oral tablet, when the oral route is contraindicated for the specific patient.

Molecules not available as FDA-approved products. Some specific molecules — many peptides, some compounded hormones like testosterone cream for women, bioidentical progesterone preparations in specific forms — exist legitimately as compounded products without equivalent FDA-approved alternatives.

Drug shortage situations. When an FDA-approved drug is on the FDA's drug shortage list, 503A compounding pharmacies are permitted to produce it temporarily to fill the supply gap. The compounded GLP-1 boom of 2022-2024 operated under this mechanism (see our piece on compounded GLP-1 FDA enforcement for the detailed regulatory picture).

What compounded medications are not appropriately used for: providing a cheaper version of an FDA-approved product that's commercially available, simply because the compounded version is less expensive. This is specifically prohibited by FDA regulations on 'essentially copy' compounding, and it's the regulatory mechanism that's currently closing the mass-market compounded GLP-1 landscape.

what this means for consumers

A few practical takeaways for consumers navigating this landscape:

Compounded is not generic. If your physician writes a prescription for a compounded medication, you're not getting a generic version of an FDA-approved product. You're getting a separately-prepared, pharmacy-specific product with its own regulatory framework. Both are legitimate; they're not the same thing.

Compounded is not 'fake.' A legitimately compounded medication prepared by a licensed pharmacy from pharmaceutical-grade active ingredients under appropriate USP standards is a real medication. It's just not FDA-approved.

Pharmacy selection matters. Not all compounding pharmacies are equal. The pharmacy's licensure, inspection history, USP compliance, and sourcing practices matter. Legitimate telehealth platforms and functional medicine practitioners work with specific compounding pharmacies that they've vetted. Gray-market online operations selling 'compounded' products with unclear pharmacy sourcing are a different and more risky category.

503A vs 503B matters for some products. For higher-volume or higher-stakes compounded products, 503B outsourcing facility production offers additional quality assurance that 503A production doesn't match. The mass-market compounded GLP-1 story involved both pathways; the informed-consumer distinction matters.

Insurance typically doesn't cover compounded. Most US health insurance plans don't cover compounded medications the way they cover FDA-approved products. This is part of the economics consumers encounter in the compounded space — often out-of-pocket payment, often different than the insurance-mediated costs of brand and generic drugs.

why this matters for peptide and hormone therapy

For readers specifically interested in peptide therapy and hormone optimization, the compounded framework is central to what's actually happening in the clinical supply chain.

Sermorelin, a GH-axis peptide available through 503A compounding pharmacies, is a compounded medication. It was FDA-approved as Geref in the 1990s but withdrawn from commercial marketing in 2008 for commercial reasons. It is now produced exclusively through 503A compounding pharmacies. It is not an FDA-approved product in its current form, even though the molecule has a long clinical history and was previously FDA-approved.

Tesamorelin is different. The branded product Egrifta remains FDA-approved for a specific indication (HIV-associated visceral lipodystrophy). Compounded tesamorelin is produced by 503A pharmacies for off-label indications (off-label body composition use, broader longevity use). The compounded version is not FDA-approved; the branded product for the specific indication is.

PT-141 (bremelanotide) has an FDA-approved branded form (Vyleesi) for generalized hypoactive sexual desire disorder in premenopausal women, and compounded preparations of the same molecule are also available through 503A pharmacies. This is an example of a compound that exists in both lanes simultaneously — the branded indication is specific, while compounded preparations cover related off-label uses.

Estradiol preparations used in modern HRT exist in both lanes too. Branded estradiol products (patches, oral forms) are FDA-approved for specific menopausal indications. Compounded estradiol formulations are produced by 503A pharmacies when a specific dose, delivery form, or combination isn't commercially available — bioidentical hormone protocols often rely on this kind of customization.

A group of peptides that were previously produced as compounded medications was moved to the FDA's Category 2 list in 2023, which pulled them out of legitimate 503A production. Whether those peptides return to Category 1 depends on an FDA reclassification process that is pending as of mid-2026. None of the peptides in that group are FDA-approved as finished pharmaceutical products, and none will become FDA-approved unless a pharmaceutical company completes an NDA for a specific indication. The regulatory framework for their legitimate availability is the compounding framework — nothing else.

For a reader trying to evaluate claims made by different telehealth platforms and functional medicine practitioners, understanding this framework matters. 'FDA-approved' and 'compounded' are different claims. Legitimate compounded products are legitimate; they're just not FDA-approved. Responsible platforms say this clearly. Less-responsible ones blur the line. Once you can see this distinction, you can read drug-marketing claims more sharply.

For related reading, see our piece on where to buy peptides legally, which covers the legitimate pharmacy and telehealth infrastructure for accessing compounded peptide preparations in the US.